Cytotoxic effects of natural and semisynthetic cucurbitacins on lung cancer cell line A549 Izabella Thaís SilvaFabiana Cristina GellerCláudia Maria Oliveira Simões PRECLINICAL STUDIES 16 January 2016 Pages: 139 - 148
Preclinical toxicity evaluation of a novel immunotoxin, D2C7-(scdsFv)-PE38KDEL, administered via intracerebral convection-enhanced delivery in rats Xuhui BaoVidyalakshmi ChandramohanDarell D. Bigner PRECLINICAL STUDIES 04 January 2016 Pages: 149 - 158
The novel pyrrolo-1,5-benzoxazepine, PBOX-15, synergistically enhances the apoptotic efficacy of imatinib in gastrointestinal stromal tumours; suggested mechanism of action of PBOX-15 Paula KinsellaLisa M. GreeneDaniela M. Zisterer PRECLINICAL STUDIES 17 February 2016 Pages: 159 - 167
A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer Dustin A. DemingLudmila L. CavalcanteGlenn Liu PHASE I STUDIES 14 December 2015 Pages: 168 - 175
Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers Elizabeth R. KesslerS. Gail EckhardtStephen Leong PHASE I STUDIES 30 December 2015 Pages: 176 - 183
A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies Geert A. CirkelBojana Milojkovic KerklaanMartijn P. Lolkema PHASE I STUDIES Open access 20 January 2016 Pages: 184 - 192
Pharmacokinetics, metabolism, and excretion of 14C-labeled belinostat in patients with recurrent or progressive malignancies Emiliano CalvoGuru ReddyLee F. Allen PHASE I STUDIES 14 January 2016 Pages: 193 - 201
Two randomized, double-blind, placebo-controlled, dose-escalation phase 1 studies evaluating BTH1677, a 1, 3–1,6 beta glucan pathogen associated molecular pattern, in healthy volunteer subjects C. E. HalstensonT. ShampM. L. Patchen PHASE I STUDIES Open access 11 February 2016 Pages: 202 - 215
A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors Jeffrey R. InfanteDavid S. MendelsonKyriakos P. Papadopoulos PHASE I STUDIES 29 February 2016 Pages: 216 - 224
A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin E 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate cancer Christos E. KyriakopoulosElisabeth I. HeathGlenn Liu PHASE I STUDIES 29 February 2016 Pages: 225 - 230
A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma Elaine McWhirterIan QuirtAmit Oza PHASE II STUDIES 03 February 2016 Pages: 231 - 235
An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer Andrea NecchiSalvatore Lo VulloFilippo G. De Braud PHASE II STUDIES 12 February 2016 Pages: 236 - 242
Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation Sumati GuptaLaunce GouwSunil Sharma PHASE II STUDIES 20 February 2016 Pages: 243 - 252
Targeting BRAF mutants in clear-cell sarcomas of soft tissue: beyond sarcoma or melanoma classification Arnaud UguenPascale MarcorellesMarc De Braekeleer SHORT REPORT 08 January 2016 Pages: 253 - 254
Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib Sadahisa OgasawaraTetsuhiro ChibaOsamu Yokosuka SHORT REPORT 14 January 2016 Pages: 255 - 260
